Repository logo
 

Research data supporting Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am


No Thumbnail Available

Type

Dataset

Change log

Authors

Bulat, Flaviu 
Hesse, Friederike 
Attili, Bala 
Solanki, Chandra 
Mendichovszky, Iosif 

Description

Helical CT data were acquired for anatomical reference and for attenuation correction using Nucline (V2.01, Mediso). Images were acquired with a semicircular scan, with 180 projections. The X-ray energy was set to 55 kVp with 600 milliseconds exposure and 1:4 image binning. Images were reconstructed using Butterworth filtering with an isotropic voxel size of 213 μm. PET images, with a nominal isotropic resolution of 0.6 mm, were reconstructed using a dynamic protocol (Tera-Tomo 3D (Mediso) algorithm), energy window 400–600 keV, coincidence modes 1–5, full detector model, normal regularization, 2 iterations, 6 subsets, with attenuation and random scatter correction. Images were an-alyzed in VivoQuant® software (vs. 4.0 patch 1, InviCRO, Needham, Massachusetts, USA). A dynamic PET acquisition lasting 120 min was initiated 30 s prior to intravenous injection of 3.7 ± 1.2 MBq 68Ga-C2Am (1075 ± 382 μg protein/kg body weight; 10 mL/kg; SA = 0.15 ± 0.05 MBq/μg protein). Scans were reconstructed into 23 time bins (4 between 0–1 min; 4 between 1–5 min; 11 between 5–60 min and 4 between 60–120 min).

Quality control consisted of ultra-performance liquid chromatography using a Superdex 75 Increase 5/150 gel filtration column (Cytiva, Emeryville, California, USA), which is designed for separating low molecular weight proteins (3 kDa to 70 kDa). Small molecules, including [68Ga]GaCl3, have long retention times (>10 min).

Correlation analysis of tumor PET signal with the histological marker of apoptosis, CC3 staining (%) was also performed and raw staining images are attached here.

Version

Software / Usage instructions

Nucline Vivoquant Chromeleon

Keywords

cell death, Molecular imaging, PET, Positron emission tomography

Publisher

Sponsorship
Cancer Research UK (S_3116)
Relationships
Supplements: